Quest Diagnostics Incorporated (DGX): Price and Financial Metrics
Quest Diagnostics Incorporated (DGX)
Today's Latest Price: $125.06 USD
Updated Jan 27 3:38pm
Add DGX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 64 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
DGX Stock Summary
- Quest Diagnostics Inc's market capitalization of $16,979,166,324 is ahead of 87.96% of US-listed equities.
- Of note is the ratio of Quest Diagnostics Inc's sales and general administrative expense to its total operating expenses; 84.13% of US stocks have a lower such ratio.
- The volatility of Quest Diagnostics Inc's share price is greater than that of merely 2.91% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to DGX, based on their financial statements, market capitalization, and price volatility, are IEX, BWA, ACGL, HEI, and AMCR.
- Visit DGX's SEC page to see the company's official filings. To visit the company's web site, go to www.questdiagnostics.com.
DGX Stock Price Chart Interactive Chart >
DGX Price/Volume Stats
| Current price | $125.06 | 52-week high | $131.81 |
| Prev. close | $125.99 | 52-week low | $73.02 |
| Day low | $124.50 | Volume | 1,200,165 |
| Day high | $127.38 | Avg. volume | 1,403,449 |
| 50-day MA | $123.30 | Dividend yield | 1.78% |
| 200-day MA | $117.55 | Market Cap | 16.85B |
Quest Diagnostics Incorporated (DGX) Company Bio
Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.
DGX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $125.06 | $206.53 | 64% |
Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 63th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 64.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Quest Diagnostics Inc ended up being:
- The company has produced more trailing twelve month cash flow than 82.16% of its sector Healthcare.
- Quest Diagnostics Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 12.06% of tickers in our DCF set.
- DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than merely 12.06% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 61% |
| 1% | 62% |
| 2% | 64% |
| 3% | 66% |
| 4% | 67% |
| 5% | 69% |
ANTM, MCK, DVA, CAH, and ANIP can be thought of as valuation peers to DGX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...